University of Miami

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Miami sits in the top decile of US sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count).

721 total trials 145 currently recruiting 430 completed early-phase tilt top decile by trial count

University of Miami: 721 sponsored US clinical trials, 145 recruiting.

University of Miami sponsors 721 registered US clinical trials on ClinicalTrials.gov, 145 of them currently recruiting, and 430 completed. 79 of these trials are in Phase 3-4 (later-stage) and 134 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 10 trials.

Top-decile sponsor footprint

University of Miami ranks in the top decile of sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 48/100

430 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

721 total, page 13 of 15

COMPLETED Phase 2

Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT00875615
COMPLETED NA

Facilitating Adjustment in Low Income Black Women With Breast Cancer

NCT02272335
COMPLETED NA

Evaluating an Exercise Program to Reduce Cardiovascular Risk Factors in Children Infected With HIV

NCT00908284
COMPLETED Phase 2

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

NCT00841100
COMPLETED

Acute Tendon and Nerve Responses to Exercise

NCT01197599
COMPLETED

6 Minute Propulsion Test Sensitivity to Increased Aerobic Capacity

NCT01184729
COMPLETED Phase 1

Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery

NCT00769145
COMPLETED NA

IgG-mediated Food Test for Weight Loss

NCT01592071
COMPLETED Phase 1

Ranibizumab for the Inhibition of Neovascularization in Pterygia

NCT00768963
COMPLETED NA

Effects of Exercise in People With Paraplegia

NCT01203150
COMPLETED NA

Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers

NCT01216735
COMPLETED NA

Vasopressin Versus Catecholamines for Cerebral Perfusion Pressure Control in Brain Injured Trauma Patients

NCT00795366
TERMINATED

Three Interacting Single Nucleotide Polymorphisms (SNPs) and the Risk of Preterm Birth in Black Families

NCT00675753
COMPLETED

Use of Hextend in Trauma

NCT00983281
COMPLETED NA

Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia

NCT02007863
COMPLETED Phase 1

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

NCT00768066
COMPLETED NA

Parent Educational Program for Children With Sickle Cell Disease

NCT00860782
COMPLETED NA

Preconditioning With Limb Ischemia for Subarachnoid Hemorrhage

NCT02411266
COMPLETED

Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface

NCT00707291
COMPLETED NA

Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide

NCT01219738
COMPLETED Phase 2

Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy

NCT00691054
COMPLETED Phase 1

Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema

NCT00826618
COMPLETED NA

Oral Polypodium Leucotomos for Melasma

NCT01162850
COMPLETED Phase 4

Primary Tube Versus Trabeculectomy Study

NCT00666237
COMPLETED Phase 3

Safety of Vitamin D Supplementation in Older Persons

NCT00681590
COMPLETED Phase 3

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

NCT01156597
COMPLETED

Wheelchair Mobility Assessment of Individuals With Spinal Cord Injury

NCT01204047
COMPLETED NA

Effects of Exercise in People With Tetraplegia

NCT01202019
COMPLETED

Coagulation Changes in Trauma Patients

NCT00795743
COMPLETED NA

Eyelash Growth From Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

NCT00773136
COMPLETED Phase 1

Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal

NCT00638651
TERMINATED NA

Timing of PDA Closure and Respiratory Outcome in Premature Infants

NCT00802685
TERMINATED Phase 4

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

NCT00854581
COMPLETED NA

Study of Resistance Strengthening Versus Ambulation Post-Liver Transplant

NCT01216722
COMPLETED NA

Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors

NCT02032121
COMPLETED

Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus

NCT00582881
COMPLETED

Optimal Fluid Resuscitation for Trauma Patients

NCT00527098
COMPLETED NA

Improving Hand and Arm Function After Spinal Cord Injury (SCI)

NCT01143597
COMPLETED Phase 2

Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers

NCT00520910
TERMINATED NA

A Randomized Clinical Study Comparing Two Closure Techniques of Excised Keloids

NCT00519493
COMPLETED Phase 2

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

NCT00499122
COMPLETED

Genetic Studies in Familial Dementia

NCT04680013
COMPLETED Phase 2

Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

NCT00503906
COMPLETED

Heart Rate Variability in Trauma Patients

NCT00795535
COMPLETED Phase 1

Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy

NCT00503568
TERMINATED Phase 1

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

NCT00503984
TERMINATED Phase 2

Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP)

NCT00450385
COMPLETED NA

Five Sessions Intervention to Facilitate Adaptation to Breast Cancer

NCT02103387
COMPLETED NA

Family-Based Drug Services for Young Disaster Victims

NCT01859000
COMPLETED

Hypothermia Following Acute Spinal Cord Injury

NCT01739010
← Previous Page 13 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 48
Phase 2 86
Phase 3 18
Phase 4 61

Therapeutic Areas

Prostate Cancer 10
Breast Cancer 9
Spinal Cord Injuries 9
Cancer 8
Amyotrophic Lateral Sclerosis 7
HIV 7
HIV Infections 6
Activity, Motor 5
Depression 5
Head and Neck Cancer 5

What is open in the University of Miami pipeline

145 recruiting of 721 indexed (20% open); 430 completed (60%).

Phase mix: 79 late (III/IV) vs 134 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (10 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Miami: open-pipeline peers nationwide

Peers matched on 721 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share University of MiamiSanofiThe University of Texas Health Science Center, HoustonIcahn School of Medicine at Mount SinaiWeill Medical College of Cornell UniversityUniversity of California, IrvineEndeavor HealthAcera SurgicalAlign Technology
University of Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 721 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Miami page

721 registered trials is a research-attention snapshot, not an endorsement of University of Miami or any single study.

  • 145 of University of Miami's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition University of Miami studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Miami pipeline card: 721 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.